UBS Group’s enVVeno Medical NVNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.46K | Sell |
243
-675
| -74% | -$7.39K | ﹤0.01% | 9269 |
|
|
2025
Q4 | $10.3K | Buy |
918
+625
| +213% | +$12.1K | ﹤0.01% | 8231 |
|
|
2025
Q3 | $9.3K | Buy |
293
+120
| +69% | +$12.3K | ﹤0.01% | 8609 |
|
|
2025
Q2 | $24.2K | Sell |
173
-135
| -44% | -$16K | ﹤0.01% | 8314 |
|
|
2025
Q1 | $28.3K | Buy |
308
+135
| +78% | +$15K | ﹤0.01% | 7982 |
|
|
2024
Q4 | $18.3K | Sell |
173
-302
| -64% | -$33.7K | ﹤0.01% | 7938 |
|
|
2024
Q3 | $55.9K | Sell |
475
-5
| -1% | -$919 | ﹤0.01% | 6743 |
|
|
2024
Q2 | $88.2K | Buy |
480
+321
| +202% | +$56K | ﹤0.01% | 6269 |
|
|
2024
Q1 | $30.2K | Buy |
+159
| New | +$28.5K | ﹤0.01% | 6739 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 9156 |
|
|
2023
Q3 | – | Sell |
-19
| Closed | -$3.17K | – | 9273 |
|
|
2023
Q2 | $2.07K | Sell |
19
-81
| -81% | -$10.5K | ﹤0.01% | 7812 |
|
|
2023
Q1 | $16.3K | Buy |
+100
| New | +$18.7K | ﹤0.01% | 7238 |
|
|
2022
Q4 | – | Sell |
-48
| Closed | -$9.75K | – | 10614 |
|
|
2022
Q3 | $11K | Buy |
48
+40
| +500% | +$8.52K | ﹤0.01% | 8315 |
|
|
2022
Q2 | $1K | Sell |
8
-8
| -50% | -$1.24K | ﹤0.01% | 9923 |
|
|
2022
Q1 | $4K | Sell |
16
-58
| -78% | -$11.3K | ﹤0.01% | 9305 |
|
|
2021
Q4 | $17K | Buy |
+74
| New | +$20.8K | ﹤0.01% | 8070 |
|
|
2021
Q3 | – | Sell |
-217
| Closed | -$56.2K | – | 9906 |
|
|
2021
Q2 | $52K | Sell |
217
-270
| -55% | -$58K | ﹤0.01% | 6393 |
|
|
2021
Q1 | $114K | Buy |
487
+453
| +1,332% | +$126K | ﹤0.01% | 5865 |
|
|
2020
Q4 | $10K | Buy |
+34
| New | +$10.5K | ﹤0.01% | 7493 |
|
|
2020
Q3 | – | Sell |
-60
| Closed | -$20K | – | 8279 |
|
|
2020
Q2 | $20K | Buy |
+60
| New | +$19.9K | ﹤0.01% | 6560 |
|
|
2020
Q1 | – | Sell |
-9
| Closed | -$4K | – | 8258 |
|
|
2019
Q4 | $4K | Buy |
9
+3
| +50% | +$1.55K | ﹤0.01% | 7672 |
|
|
2019
Q3 | $4K | Buy |
+6
| New | +$5.22K | ﹤0.01% | 7561 |
|
|
2019
Q2 | – | Sell |
-8
| Closed | -$10K | – | 8065 |
|
|
2019
Q1 | $10K | Sell |
8
-9
| -53% | -$13K | ﹤0.01% | 6815 |
|
|
2018
Q4 | $22K | Buy |
+17
| New | +$30.6K | ﹤0.01% | 6703 |
|
|
2018
Q3 | – | Hold |
0
| – | -$1K | – | 8167 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7826 |
|
Other funds holding NVNO
KCM
CM
VCM
VFT
WIM
TRCT
UBS Group's NVNO Position: Q1 2026 in Review
UBS Group reduced its enVVeno Medical (NVNO) stake by 74% in Q1 2026, selling an estimated $7.39K and leaving 243 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #9269.
UBS Group first reported a position in NVNO in Q4 2018 and has held it in 23 quarters since. The position peaked at $114K in Q1 2021. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.
- UBS Group held 243 shares of enVVeno Medical worth $2.46K as of Q1 2026.
- UBS Group sold 675 enVVeno Medical shares in Q1 2026, an estimated $7.39K.
- enVVeno Medical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9269 holding.
- UBS Group first reported a position in enVVeno Medical in Q4 2018 and has held it in 23 quarters since.
- UBS Group's enVVeno Medical position peaked at $114K in Q1 2021.
- 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.